Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Cost Of AstraZeneca's Break-Up With Merck On Track To Be $3.3 Bil.

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Joint venture exit will allow AstraZeneca more freedom to in-license products, executives say.

You may also be interested in...



As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts

The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.

J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business

The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.

US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say

US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By